Prime Medicine (PRME) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.22

Estimate

-$0.24

Surprise

+8.0%

Revenue (period 2026-09-30)

$4.2M

Score today

5.0/10

Revenue source: xbrl.

Prime Medicine (PRME) reported a narrower loss than forecast — adjusted EPS of -$0.22 against the -$0.24 estimate (a 8.0% beat on a still-unprofitable quarter).

• Prime Medicine Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-12
• Prime Medicine Q3 EPS $(0.22) Beats $(0.25) Estimate, Sales $4.213M Beat $1.206M Estimate — benzinga, 2026-11-12
• Prime Medicine Closes Underwritten Public Offering Of 41,071,428 Common Shares For Gross Proceeds Of ~$143.7M — benzinga, 2026-11-12

TrendMatrix currently rates PRME Sell at 5.0/10; no pre/post engine snapshot brackets this report.

3 of the last 4 quarters beat the estimate; this quarter's +8.0% surprise compares with a +2.1% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$3.89

Price target

$6.43

Stop

$3.62

Upside to target

+65.3%

Reward-to-risk

4.3:1

Model outputs from TrendMatrix’s engine as of 2026-11-13 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$705.6M

P/E (fwd)

-4.3

52-week range

$2.67–$5.91

Off 52-week high

34.2%

RSI (14)

52

Volume vs avg

1.24×

Score today

5.0/10